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Introduction
Ultra-large von Willebrand factor (UL-VWF) secreted by activated endothelial cells or platelets is cleaved into smaller multimers by ADAMTS-13 (A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13) to reduce the thrombotic potential of UL-VWF. Deficiency in ADAMTS-13 activity, either because of a congenital defect or the presence of autoantibodies, is associated with thrombotic thrombocytopenic purpura (TTP) [1] . TTP is a thrombotic microangiopathy (TMA) defined by thrombocytopenia and hemolytic anemia [2] , caused by VWF-rich microthrombi blocking the capillaries. As a result, patients may suffer from fever, neurological disorders, impaired renal function, cardiac disorders, and eventually death when left untreated.
Typically, patients suffer from acute (recurrent) episodes of TTP, often as a result of a secondary trigger, such as infection, pregnancy, cancer, bone marrow transplantation and use of certain drugs (e.g. quinine or ticlopidine). Patients can, however, achieve clinical remission despite a persistent deficiency in ADAMTS-13 activity. A more thorough understanding of this ambiguous pathophysiology is highly necessary to improve patient treatment. We previously investigated the involvement of an auxiliary VWF-cleaving protease in the pathophysiology of TTP: the fibrinolytic enzyme plasmin. Increased plasmin activity was detected in patients with acute TTP, suggesting a possible role for plasmin in controlling VWF activity [3] . In vitro, plasmin is indeed able to cleave shear-unfolded VWF multimers and even ADAMTS-13-resistent VWF fibers that form under pathological shear rates [3] [4] [5] [6] [7] . Susceptibly of VWF to plasmin proteolysis is modulated by N-linked glycan expression in VWF A1A2A3, and a K1491-R1492 peptide bond within the A1-A2 linker region of VWF was demonstrated to be the cleavage site for plasmin [7] . Exogenous activation of plasmin using the thrombolytic agent streptokinase reduced TTP signs in vivo [3] , and hence, plasmin-induced cleavage of VWF might be of both physiological and pharmacological significance during acute TTP.
Plasminogen can be activated into plasmin predominantly by tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Because of its high affinity towards fibrin, tPA is considered the most important plasminogen activator during fibrinolysis [8] . uPA has a low affinity for fibrin but becomes an efficient plasminogen activator in the presence of the uPA receptor (uPAR) [9] . Increased uPAR expression is amongst others present on hypoxic endothelial cells [10] , on activated leukocytes [11] and in brain lesions after traumatic brain injury [12] . Interestingly, increased uPAR expression was also detected in glomeruli and vascular walls in renal biopsies obtained from patients with acute TTP/hemolytic uremic syndrome (HUS) [13] . Plasmin activity is tightly regulated to protect against unrestricted proteolytic activity, mainly by three inhibitors: (i) plasminogen activator inhibitor 1 (PAI-1), which inhibits uPA and tPA, thereby reducing plasminogen activation, resulting in decreased plasmin levels, (ii) a2-antiplasmin, which forms a plasmin-a2-antiplasmin (PAP) complex with plasmin, resulting in inhibition of plasmin activity and (iii) thrombinactivatable fibrinolysis inhibitor (TAFI), which in the presence of thrombin/thrombomodulin protects the fibrin clot against lysis.
Because of the short half-life of circulating free plasmin, evaluation of in vivo plasmin activity is generally carried out by measuring PAP-complex levels [14] . In a previous study, we have identified elevated PAP-complex levels in acute TTP patients [3] . With the ability of plasmin to proteolyse VWF, plasmin was seen as a possible back-up for ADAMTS-13. Therefore, in the current study, we investigated whether elevated endogenous plasmin levels are able to reduce the presentation of biological and clinical features of acute TTP in both mice and humans.
Materials and methods

Patient studies
Since 2000, all patients with a presumptive diagnosis of TMA have been enrolled prospectively and consecutively in the national Registry of the French Reference Center for TMA (Paris, France), after obtaining appropriate consent, according to the Declaration of Helsinki. Citrated plasma samples were collected from adult patients during acute TTP episodes before any treatment was started (n = 44), and during remission when acute signs and symptoms were no longer present (n = 40). Healthy donors were age and gender matched to the TTP patients (n = 26). Baseline characteristics are described in Table 1 .
Blood collection, plasma preparation and measurement of ADAMTS-13 activity were performed as described before [15] . Routine laboratory tests including platelet count, hemoglobin level, presence of schistocytes in the blood smear and hemolysis exploration (haptoglobin, bilirubin and lactate dehydrogenase activity) were performed according to conventional methods in each center. Anti-ADAMTS-13 IgG titers were measured using the Technozym Ò ADAMTS-13 INH ELISA assay (Technoclone, Vienna, Austria) according to the manufacturer's instructions [16] . Patients were diagnosed with an acquired ADAMTS-13 deficiency when anti-ADAMTS-13 antibodies were detectable and/or if ADAMTS-13 activity recovered during remission. Medical records were extensively analyzed to collect clinical and biological features of the acute episode of TTP, including the presence of fever, neurological disorders, impaired renal function and cardiac ischemia [16] .
Murine model of acquired TTP
Animal studies were approved by the Institutional Animal Care and Use Committee of KU Leuven (project number: P162/2014). Male C57BL/6 (Jackson Laboratory, Bar Harbor, ME, USA) and a2-antiplasmin À/À and a2-antiplasmin +/+ mice [17] (C57BL/6-129SVj background) with a bodyweight of 16-25 g were used for in vivo experiments. To mimic acquired ADAMTS-13 deficiency, mice were intravenously injected with the inhibitory monoclonal murine anti-ADAMTS-13 antibodies 14H7 and 13B4 (1.25 mg kg À1 each) [17] . Mice were triggered after 24 h by an intravenous injection with 2000 U kg À1 recombinant (r)VWF to develop TTP signs [18] . Inhibition of PAI-1 was established by injections of monoclonal anti-PAI-1 MA-MP6H6 [19] , with isotype-matched antibody MA-Tom1-41B2 as a control.
Blood was collected at baseline (7 days before the start of the experiment) and 6 and/or 24 h after rVWF injections, on trisodium citrate (5:1 vol/vol of blood:3.8% sodium citrate) or EDTA (10:1 vol/vol of blood:0.5 M EDTA) via retro-orbital venipuncture. Total blood cell counts were determined in EDTA blood using the Hemavet 950 (Drew Scientific, Dallas, TX, USA). Plasma was obtained from blood collected on citrate by centrifugation at 2500 9 g for 6 min and stored at À80°C.
Determination of PAP-complex, PAI-1 and uPA levels in plasma PAP-complex levels in patient plasma were determined using ELISA. Antibodies MA-34F7 and MA-7B9 against a2-antiplasmin were used as capturing antibodies and biotin-labeled anti-plasminogen antibody MA-34D3 as a detection antibody [20, 21] . Horseradish peroxidase (HRP)-conjugated streptavidin (Sigma Aldrich, Diegem, Belgium) was added and colorimetric development was performed using o-phenylenediamine dihydrochloride (OPD; Sigma Aldrich) and H 2 O 2 (Thermo Fisher Scientific, Geel, Belgium). The reaction was stopped by adding 4M sulfuric acid (Thermo Fisher), after which the absorbance was determined at 490 nm. Total PAI-1 levels were measured using the anti-PAI-1 capturing antibody MA-31C9 and detecting antibody MA-55F4C12-HRP [22] . Active PAI-1 was measured using capturing antibody MA-21F7C4, recognizing PAI-1 in complex with tPA. Plasma with or without an excess of tPA (20 U mL À1 ) was next added, resulting in complex formation of free active PAI-1 with tPA. Next, antibody MA-51H8 recognizing tPA was added. The concentration of active PAI-1 was calculated by subtracting endogenous PAI-1:tPA complex from the total generated PAI-1:tPA complex [22] . uPA antigen levels were determined according to the manufacturer's instructions (Technozym Ò u-PA ELISA kit, Technoclone). In murine plasma samples, PAP-complex levels were measured by polyclonal rabbit anti-mouse-a2-antiplasmin as a capturing antibody, and biotin-labeled polyclonal rabbit anti-mouse plasminogen as a detection antibody [23] . Murine plasma activated with tPA (Actilyse Ò , Boehringer Ingelheim, Ingelheim am Rhein, Germany) was added in serial dilutions as a standard. Total murine PAI-1 levels were determined with anti-PAI-1 antibody MA-P2H2 as a capturing and polyclonal rabbit antimouse PAI-1 as a detection antibody, followed by goatanti-rabbit HRP and OPD substrate [19] .
VWF multimer analysis
VWF multimer analysis on murine plasma was performed as described [24, 25] . Briefly, VWF was separated on sodium dodecyl sulfate (SDS) 1.5% iso electric focusing agarose gels. The gels were fixed on Gelbond (Cambrex Bio Science Rockland Inc., Rockland, ME, USA) and VWF was detected using anti-human VWF immunoglobulins labeled with alkaline phosphatase and visualized using a substrate kit (BioRad, Hercules, CA, USA). Densitometric analysis was performed using ImageJ software (version 1.48, National Institute of Health, Bethesda, MD, USA). For each lane, the density of the complete multimer was graphed. The low (LMW, band 1-5), intermediate (MMW, band 6-10) and high-molecular-weight, including UL-VWF (HMW; > 10 bands) multimers were selected and the density of each relative to the complete multimer density (= 100%) was calculated.
In vivo VWF string survival time Male mice were anesthetized by an intraperitoneal injection of Xylazine (100 mg kg À1 ) and Ketamine
). Platelets were labeled using rhodamine 6G (1 lg g À1 bodyweight; Invitrogen, Ghent, Belgium) that was injected intravenously. Mesenteric blood vessels were exposed through an incision in the abdominal wall and mesenteric venules were injured using 10% FeCl 3 . String survival time (SST) was determined as described previously [26] . Images were recorded with a 20x objective on a Nikon eclipse TE200 inverted microscope (Nikon Instruments, Melville, NY, USA) connected to a Hamamatsu CCD camera (ORCA-R2, Hamamatsu Photonics, Hamamatsu City, Japan), using HCImage software version 2.0 (Hamamatsu Photonics).
Statistics
All data are presented as median AE interquartile range (IQR). Statistical comparisons between two groups were performed by the Mann-Whitney U-test. Statistical tests were performed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). A P-value of less than 0.05 was considered significant and is indicated with an asterisk (*); a P-value < 0.01 is indicated with two asterisks (**).
Results
TTP in mice is associated with increased PAP-complex and PAI-1 levels
We have previously demonstrated that in vivo plasmin activity, detected by the presence of circulating PAP-complex levels, is increased in patients with acute TTP [3] . However, it remained unclear (i) why the elevated plasmin levels during acute TTP were not sufficient to act as a back-up mechanism for ADAMTS-13 deficiency in these patients and (ii) if circumstances exist where plasmin could do so. We aimed to answer these questions by using our mouse model of acquired TTP [17] . To investigate plasmin activity during acute TTP in more detail, the TTP mouse model also should have elevated plasmin activity during acute TTP comparable to what we observed in TTP patients. Hence, we investigated whether mice with acquired TTP signs had elevated PAP complexes. Acquired TTP was induced by injecting C57BL/6 mice with inhibitory monoclonal anti-ADAMTS-13 antibodies 14H7 and 13B4 [17] , followed by a trigger with 2000 U kg À1 rVWF [18] 1 day later.
After 24 h, mice developed TTP signs as they presented with severe thrombocytopenia (Fig. 1A ) and decreased hemoglobin levels as a measurement of anemia (Fig. 1B) .
Comparable to TTP patients [3] , mice suffering from TTP signs presented with significantly increased PAP-complex levels ( Fig. 1C) , demonstrating that active plasmin was generated during acute TTP as a result of the vascular damage. However, plasmin generated during acute TTP is clearly not sufficient to resolve TTP signs. Active plasmin can be directly inhibited by a2-antiplasmin, resulting in increased PAP-complex levels. Moreover, other inhibitors could possibly control and limit the initially formed plasmin. Indeed, in mice suffering from TTP, we also measured significantly increased total PAI-1 antigen levels (Fig. 1D ). This demonstrates that plasmin activity is controlled during acute TTP in mice.
Absence of either PAI-1 or a2-antiplasmin does not resolve acute TTP signs
The elevated PAI-1 levels suggest that plasmin inhibition might limit the potential beneficial effect of plasminmediated VWF cleavage in acute TTP. Therefore, we investigated whether blockage of PAI-1 or absence of a2-antiplasmin would allow generation of amounts of plasmin sufficient to influence TTP outcome. Blocking of PAI-1 was realized by injecting C57BL/6 mice with an acquired ADAMTS-13 deficiency with the PAI-1 inhibitory monoclonal antibody MA-MP6H6 [27] 24 h before TTP was triggered with rVWF. Control mice were injected with the isotype-matched antibody MA-Tom1-41B2. In the absence of PAI-1 activity, mice still presented with thrombocytopenia ( Fig. 2A) and anemia (decreased hemoglobin levels; (A, B) Total blood cell counts were performed on EDTA anticoagulated blood at baseline (À7 days) and day 1 (24h) after rVWF injection to determine platelet count and hemoglobin levels. (C) PAPcomplex levels and (D) PAI-1 levels were determined in citrated plasma using ELISA. **P < 0.01.
inhibition does not result in a decrease in TTP signs. Nonetheless, PAP-complex levels were increased to a greater extent in mice with inhibited PAI-1 compared with mice with normal PAI-1 (Fig. 2C) , indicating that inhibition of PAI-1 did result in increased plasmin activity in vivo during acute TTP signs. As the plasmin activity pathway is tightly regulated via several inhibitors, with also a prominent role for a2-antiplasmin by directly inhibiting plasmin, we investigated the role of a2-antiplasmin by subjecting a2-antiplasmin À/À mice to our acquired TTP model. Also in these mice, triggering TTP with rVWF resulted in decreased platelet and hemoglobin levels comparable to a2-antiplasmin +/+ mice (Fig. 2D, E) , demonstrating that absence of a2-antiplasmin also did not affect the presentation of TTP signs.
Amplified endogenous plasmin activity results in recovery from TTP signs Next, we investigated whether a dual deficiency in both a2-antiplasmin and PAI-1, hence resulting in amplified endogenous plasmin activity, would result in recovery from TTP signs. To test this, ADAMTS-13 activity was blocked in a2-antiplasmin À/À mice in which also PAI-1 activity was inhibited by monoclonal antibody treatment and TTP was triggered using rVWF. These acquired ADAMTS-13-deficient a2-antiplasmin À/À mice with inhibited PAI-1 demonstrated a decreased platelet count after 6 hours, the time-point at which vascular obstructions are already formed in this TTP model [18] . However, all mice recovered from thrombocytopenia within 24 h (Fig. 3A) . Control a2-antiplasmin +/+ mice with an acquired deficiency of ADAMTS-13 and injected with an isotype matched antibody (i.e. maintaining normal PAI-1 levels) suffered from severe thrombocytopenia at 6 and 24 h after rVWF injection (Fig. 3A) . Hemoglobin levels, however, were not decreased in mice with recovered platelet counts (Fig. 3B ), in agreement with previous observations that anemia recovers more slowly during TTP treatment [25] . Together, these results indicate not only that the presence of acute TTP activates the plasminogen pathway, but furthermore that when amplified plasmin Absence of either plasminogen activator inhibitor 1 (PAI-1) or a2-antiplasmin does not resolve acute thrombotic thrombocytopenic purpura (TTP) signs. C57BL/6 mice deficient in PAI-1 by injection of inhibitory anti-PAI-1 (or isotype control) antibodies at day À1 (A, B, C) or a2-antiplasmin À/À and a2-antiplasmin +/+ mice (D, E) were made deficient in ADAMTS-13 by injection of inhibitory anti-ADAMTS-13 antibodies on day À1. TTP was triggered using 2000 U kg À1 recombinant von Willebrand factor (rVWF) on day 0. Total blood cell counts were performed on EDTA anticoagulated blood at baseline (À7 days) and day 1 (24h) after rVWF injection to determine platelet count (A, D) and hemoglobin levels (B, E). Plasmin-a2-antiplasmin (PAP)-complex levels (C) were determined in citrated plasma using ELISA. **P < 0.01.
activity is allowed, plasmin can control acute TTP, resulting in the resolution of TTP signs.
Amplified endogenous plasmin activity results in increased VWF proteolysis
Measuring PAP-complex levels in these mice to confirm the increased plasmin activity in vivo is not possible because of the absence of a2-antiplasmin. Therefore, to confirm our hypothesis that TTP signs were resolved due to increased VWF proteolysis as a result of amplified plasmin activity, we performed VWF multimer analysis. The VWF multimer pattern in plasma from mice 24 h after challenge with rVWF was analyzed and the percentage of HMW VWF multimers was quantified. A lower percentage of HMW VWF multimers was observed in plasma from mice with amplified plasmin activity compared with control mice (Fig. 4A , representative multimer image in Fig. 4B , representative densitometry traces in Fig. 4C ), suggesting increased VWF proteolysis in vivo.
To confirm these results, we used a VWF string cleavage model [26] to demonstrate increased VWF cleavage in mice with amplified plasmin activity. Mesenteric venules of wild-type (WT; both C57BL/6 and a2-antiplasmin +/+ ) mice, a2-antiplasmin À/À mice, C57BL/6 mice with inhibited PAI-1 and a2-antiplasmin À/À mice with inhibited PAI-1, were injured using topical application of FeCl 3 solution. Downstream of the formed thrombus, VWF strings were released by the injured endothelial cells and remained attached to the endothelial surface for a certain period of time (string survival time, SST). In WT mice, a 2-fold prolonged SST was observed when ADAMTS-13 was inhibited ( Fig. 4D ; representative images in Fig. 4E ), confirming reduced VWF proteolysis in the absence of active ADAMTS-13. In the presence of ADAMTS-13 activity, a2-antiplasmin À/À mice, C57BL/6 mice with inhibited PAI-1 or a2-antiplasmin À/À mice with inhibited PAI-1 all had an SST similar to WT mice (Fig. 4E) , indicating that plasmin does not markedly influence VWF cleavage when ADAMTS-13 is present.
In the absence of ADAMTS-13 activity, however, the SST in a2-antiplasmin À/À mice decreased 1.6-fold compared with wild-type mice without ADAMTS-13 activity, demonstrating that when increased plasmin activity is allowed, plasmin facilitates VWF string proteolysis. Additionally, C57BL/6 mice with inhibited PAI-1, as well as a2-antiplasmin À/À mice with inhibited PAI-1, demonstrated a similar SST as mice with normal ADAMTS-13 activity ( Fig. 4E ; representative images in Fig. 4D ). Using this VWF string cleavage model, it is demonstrated that when amplified plasmin activity is allowed, UL-VWF is cleaved to a similar extent to that by ADAMTS-13. These results indicate an important role for PAI-1 and a2-antiplasmin in the modulation of plasmin-mediated proteolysis of UL-VWF in mice with defective ADAMTS-13.
Increased PAP-complex and active PAI-1 levels in patients with acute TTP
In mice, we have demonstrated that the presence of PAI-1 and a2-antiplasmin explains why plasmin generated during acute TTP does not rescue TTP. Whether the same is true in TTP patients is not known. To gain more insight into this matter, we measured the levels of PAP complex and PAI-1 in TTP patients. We previously reported that during the acute phase of TTP, patients had mice were injected with anti-plasminogen activator inhibitor 1 (PAI-1) antibodies and a2-antiplasmin +/+ mice with isotype control antibodies on day À1. All mice were made deficient in ADAMTS-13 by injection of inhibitory anti-ADAMTS-13 antibodies at day À1. TTP was triggered using 2000 U kg À1 recombinant von Willebrand factor (rVWF) at day 0. (A, B) Total blood cell counts were performed on EDTA anticoagulated blood at baseline (À7 days) and 6 and 24 h after rVWF injection to determine platelet count (A) and hemoglobin levels (B). **P < 0.01. ). ADAMTS-13 activity levels during the acute phase were severely decreased (< 5% of normal) compared with patients in remission (69% [IQR 56-95%]). Significantly elevated PAP-complex levels were observed in acute TTP patients compared with patients in remission and healthy donors (Fig. 5A) , confirming our previous data [3] .
Elevation of total PAI-1 antigen levels during acute TTP has been demonstrated before [28] [29] [30] . However, active PAI-1 levels are clinically more relevant, as obviously only active PAI-1 is responsible for the inhibition of the plasminogen activators. Non-active (latent) PAI-1 is mostly released from platelets and can bias total PAI-1 antigen assays [22, 31] . Total PAI-1 (data not shown) and active PAI-1 levels (Fig. 5B) were elevated during acute TTP compared with TTP patients in remission and healthy donors. These results suggest that plasminogen activation during acute TTP is controlled and suppressed by PAI-1. uPA levels in patients with acute TTP were lower compared with healthy donors and patients in remission (Fig. 5C) . Additionally, uPA levels inversely correlated with active PAI-1 levels (r = À0.4536, P = 0.0026), demonstrating inhibition of uPA by PAI-1 and suggested, as described in literature, subsequent cellular internalization and degradation of the uPA/PAI-1 complexes [32] . Despite elevated PAP-complex levels, acute TTP patients still suffer from severe symptoms and hence the activated plasmin is not sufficient to remove all occlusive VWF-rich microthrombi. The level of PAP complexes and hence the degree of plasmin activity did not influence disease signs and outcome during acute TTP episodes; no significant difference in PAP-complex levels was observed in patients with or without the presence of the following signs during the acute phase: fever, neurological disorders, impaired renal function, cardiac ischemia and death (Table 2, Figure S1A -E). Accordingly, no correlation was observed between PAP-complex levels and creatinine levels, nor between PAP-complex levels and urea concentration ( Figure S1F, G) . Comparable to PAP-complex levels, active PAI-1 levels were also not associated with disease signs and outcome (Table 2) . Altogether, these results demonstrate that endogenously generated plasmin levels are not high enough to reverse acute TTP in both mice as well as in TTP patients because of the presence of inhibitors. Only if amplified plasmin activity is allowed by targeting the inhibitors, can TTP signs be reversed as a result of an increased proteolysis of VWF.
Discussion
Plasmin is capable of cleaving VWF and was suggested to play a role in TTP pathophysiology. In the current study, we demonstrated that although plasmin activity is elevated during acute TTP episodes, these increased plasmin levels are not high enough to have a substantial impact on TTP outcome because of the presence of plasmin(ogen) inhibitors. Interestingly, allowing amplified endogenous plasmin activity in mice does result in the resolution of acute TTP signs by increased proteolysis of VWF. Although it is clear that endogenously generated plasmin is insufficient to fully prevent acute TTP, this study supports the pharmacological opportunities plasminogen activation could provide in TTP treatment.
Elevated PAP-complex levels were demonstrated during acute TTP in both our patient cohort and in the ADAMTS-13-deficient mice triggered with rVWF. Elevated PAP-complex levels are a reliable marker to assess the amount of plasmin formed in vivo [14] as PAP complexes already account for AE 90% of in vivo plasmin inhibition [14] . However, next to a2-antiplasmin, also other inhibitors, such as a2-macroglobulin, can form a complex with plasmin. In the current study, using mouse models, we demonstrated that the increased plasmin levels are not sufficient to prevent acute TTP, most likely because plasmin activity is inhibited by a2-antiplasmin, but also because of increased levels of PAI-1 preventing the generation of plasmin. Indeed, when we inhibited PAI-1 in a2-antiplasmin À/À mice (i.e. when amplified endogenous plasmin is present in mice), plasmin-mediated proteolysis of VWF did resolve TTP signs. The tightly regulated plasminogen activation pathway might therefore prevent the supraphysiological plasmin activity levels required to achieve complete VWF proteolysis during acute TTP. In line with this, in our TTP patient cohort, neither highly elevated nor very low PAP-complex levels correlated with clinical features or outcome during the acute phase of TTP, suggesting that endogenous plasmin activity does not influence acute TTP. Whether the elevated plasmin activity levels during acute TTP have any effect on other processes targeted by plasmin (e.g. elimination of misfolded proteins or activation of cell migration or proteolysis) [33] [34] [35] [36] remains unknown and is an interesting subject for future studies. Active PAI-1 can block both uPA and tPA-induced plasminogen activation. Tissue ischemia, as present during acute TTP, triggers the secretion of uPA [37] and tPA [38] . Previous studies have demonstrated increased tPA levels during acute TTP [28] . With an absence of fibrinrich microthrombi in TTP pathology [39] and the absence of plasmin generation by tPA on VWF strings [6] , a prominent role for tPA in plasmin generation is not expected and activation of plasminogen most likely occurs on the cell surface. On this cell surface, plasminogen is bound to cellular plasminogen receptors and when uPA binds to its receptor uPAR, plasminogen can efficiently be converted into plasmin [40] . Cell-bound plasmin is protected from inhibition by a2-antiplasmin; however, dissociation of plasmin from the cell surface results in rapid inhibition of plasmin activity [40] . In our patient cohort, we measured decreased levels of uPA in patients with acute TTP. Decreased levels of uPA are a direct result of higher PAI-1 levels, as uPA/PAI-1 complexes are internalized and subsequently degraded via uPAR-expressing cells [32, 41] . Indeed, increased uPAR expression was detected in glomeruli and vascular walls in renal biopsies obtained from patients with acute TTP/HUS [13] , demonstrating a role for uPA/uPAR-mediated plasminogen activation in TTP.
Therapeutic strategies interfering with the regulation of plasmin activity (e.g. by inhibition of PAI-1 or a2-antiplasmin) might be helpful in the management of acute TTP episodes. However, this may come with a bleeding risk, when plasmin activity is no longer controlled by its biological inhibitors. Fibrin is the primary substrate for plasmin, but next to its role in fibrinolysis, plasmin is amongst others involved in cell migration [34] , wound healing [35] and proteolysis of extracellular matrix proteins [36] . The diverse roles of plasmin, the need to overrule the present inhibitors and the lower affinity of plasmin towards VWF compared with fibrin [42] , illustrate the requirement for supraphysiological plasmin activity levels for the resolution of TTP signs. In a previous study, we have demonstrated that exogenous activation of plasmin using streptokinase reduces TTP signs [3] . Thrombolytic agents might therefore serve as a good alternative to temporarily increase plasmin activity levels to supraphysiological concentrations. Our murine studies demonstrated that a low-dose streptokinase was sufficient to restore platelet counts without apparent side-effects. Nevertheless, preclinical studies with streptokinase and other (non-immunogenic) thrombolytic agents are highly required to assess the efficacy and safety when using plasmin activation as a treatment for acute TTP. Safety assessment includes the risk of bleeding, but also the effect of enhanced plasmin activation on other substrates of plasmin besides VWF, resulting in, for example, proteolysis of extracellular matrix proteins and fibrinogen degradation. In support of the bleeding risk, interfering with the hemostatic process (e.g. by the anti-VWF nanobody caplacizumab) was demonstrated to be safe for the treatment of patients with TTP without causing any severe bleeding events [43] .
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